Joy as NICE changes tack on first NHS vitiligo treatment
NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.
Newsletters and Deep Dive digital magazine
NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.
The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.
For patients and GPs, accessing NHS services can feel like a "maze of dead ends and detours," according to a new poll.
Amid reports that a shortage of bone cement in the UK is leading to delayed orthopaedic surgeries, Biocomposites has brought forward a product launch.
Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.
Editor's Picks
Newsletters and Deep Dive
digital magazine